These two bellwether trials may provide important insight into how juries will react to evidence put forth in similar lawsuits involving Lipitor and diabetes.
New York, New York (PRWEB) April 24, 2015
Lipitor lawsuits (http://www.lipitorlawsuitcenter.com/) continue to move forward in the federal multidistrict litigation underway in U.S. District Court, District of South Carolina. According to court documents, the parties involved in the proceeding submitted a Joint Status Report on April 16th detailing, among other things, preparation for the litigation’s upcoming bellwether trials. The report notes that counsel for both plaintiffs and defendants have conducted depositions of non-party fact witnesses in the two cases selected for trial. Depositions of plaintiffs’ experts are expected to take place by June 5, 2015. (In re Lipitor (Atorvastatin) Litigation, MDL No. 2502)
“As our Firm is representing plaintiffs in this proceeding, we are very pleased that bellwether discovery is continuing to progress. These two bellwether trials may provide important insight into how juries will react to evidence put forth in similar lawsuits involving Lipitor and diabetes,” says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing numerous victims of defective medical devices and drugs including Lipitor. The Firm continues to offer free and confidential Lipitor lawsuit evaluations to individuals who developed diabetes after use of this cholesterol statin.
According to court documents, nearly 2,200 Lipitor lawsuits are currently pending in the District of South Carolina, all of which accuse Pfizer, Inc. of failing to warn that use of its statin medication could increase the risk that a patient will develop Type 2 diabetes. Among other things, the complaints note that the U.S. Food & Drug Administration (FDA) announced in February 2012 that all statin labels would be updated to include information about their potentially harmful effects on blood glucose levels. However, plaintiffs claim that the label modifications Pfizer made in the wake of this announcement were not sufficient to warn patients about the association between Lipitor and diabetes.
Court records indicate that jury selection for the Lipitor litigation’s first bellwether trial is set to begin on November 4, 2015. (Case No. 2:2015cv01132) The second case is expected to go before a jury in late 2015 or early 2016. (Case No. 2:2014cv01879)
Individuals who allegedly developed Type 2 diabetes due to their use of Lipitor may be eligible to pursue their own lawsuit against Pfizer. To learn more about filing a Lipitor lawsuit, please visit Bernstein Liebhard LLP’s website. To arrange for a free case review, please call 800-511-5092.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have ben able to recover more than $3 billion on behalf of our clients. The National Law Journal has recognized Bernstein Liebhard for twelve consecutive years as one of the top plaintiffs' firms in the country. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2015 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Sandy A. Liebhard, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com